TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17042842
Drug: Intravenous granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous granisetron 1 mg
Study: 11129548
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg plus dexamethasone 0.5 mg (then 0.25 mg)
Study: 24630685
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard PCa therapy alone)
Study: 16533451
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 800 mug
Study: 8340625
Drug: Buccal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal approach with surgical bur
Study: 3519731
Drug: Streptokinase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase therapy (combined intravenous and intracoronary)
Study: 3519731
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard coronary care unit treatment)
Study: 27174526
Drug: Edaravone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (60 mg/d) administered from the day of surgery to postsurgical day 7
Study: 27174526
Drug: Edaravone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (60 mg/d)
Study: 22414705
Drug: Propranolol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (a beta adrenergic antagonist)
Study: 19941990
Drug: CDA1 (10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDA1 (10mg/kg intravenous infusion)
Study: 12594635
Drug: Lipid formulation
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid formulation of amphotericin B (L‐AmB), 10 mg/kg daily for 2 days
Study: 12594635
Drug: Lipid formulation
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid formulation of amphotericin B (L‐AmB), 4 mg/kg daily for 5 days
Study: 10556145
Drug: Gentamicin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 160 mg via dry powder inhaler (DPI)
Study: 10556145
Drug: Gentamicin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin at 5 mg/kg by intravenous infusion
Study: 8737325
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.25 g creatine monohydrate per kg body mass)
Study: 29651970
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg per day)
Study: 25567010
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (HepB) administered on 0-1-6 schedule
Study: 25567010
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (after first-dose revaccination)
Study: 25567010
Drug: Anti-HBc alone
Normalized name: Aminosyn-HBC 7 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HBc alone (after first-dose revaccination)
Study: 25567010
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (after third-dose revaccination)
Study: 25567010
Drug: Anti-HBc alone
Normalized name: Aminosyn-HBC 7 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HBc alone (after third-dose revaccination)
Study: 22873342
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gruel (30-40 mL daily)
Study: 20415082
Drug: Traction (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traction (5 to 6 kg, 20 minutes each time, once every other day) and Nimodipine (40 mg, 3 times a day for 3 weeks)
Study: 17903344
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 600 mg
Study: 17903344
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 1200 mg
Study: 17903344
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 0 mg (control)
Study: 10487455
Drug: Topical nystatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nystatin cream
Study: 1465747
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (200 micrograms, one puff twice daily)
Study: 29369159
Drug: Tox+ for
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tox+ for stimulants (methamphetamine or cocaine)
Study: 29369159
Drug: Tox+ for
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tox+ for stimulants
Study: 22222478
Drug: Skilled manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skilled manual control of propofol and remifentanil using target-controlled-infusion systems
Study: 16217721
Drug: Speech Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech Therapy Assessment (STA)
Study: 12017395
Drug: Enteric-coated diclofenac
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteric-coated diclofenac sodium 50 mg (3 doses of 50 mg every 8 hours)
Study: 2142700
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg dexamethasone
Study: 16321619
Drug: Oral alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alfentanil (23, 30, 43, or 75 microg/kg)
Study: 11986452
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam plus oral transmucosal fentanyl (5-10 microg/kg)
Study: 11986452
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam plus placebo
Study: 11986452
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam plus oral transmucosal fentanyl
Study: 9535154
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg urapidil orally
Study: 2761587
Drug: Aspirin (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1300 mg daily)
Study: 28445631
Drug: CBT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT with Exposure Therapy (CBT/Exposure)
Study: 28445631
Drug: CBT without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBT without Exposure Therapy (CBT)
Study: 26081486
Drug: Sucrose-sweetened soft
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose-sweetened soft drinks (SSSDs) - 1 l daily for 6 months
Study: 26081486
Drug: Isocaloric semi-skimmed
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric semi-skimmed milk - 1 l daily for 6 months
Study: 26081486
Drug: Diet cola
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet cola - 1 l daily for 6 months
Study: 26081486
Drug: Water -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water - 1 l daily for 6 months
Study: 15338971
Drug: 81 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg/day aspirin
Study: 15338971
Drug: 325 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg/day aspirin
Study: 15338971
Drug: baseline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline (no aspirin)
Study: 11341854
Drug: naloxone/lofexidine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone/lofexidine combination treatment
Study: 11341854
Drug: lofexidine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lofexidine monotherapy
Study: 8216441
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg/d
Study: 28895379
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at a target effect‐site concentration of 7 ng×mL‐1
Study: 23942318
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) plus treatment as usual (TAU)
Study: 17764606
Drug: Free iron/folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free iron/folic acid tablets (treatment, n = 109)
Study: 17764606
Drug: Prescription to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription to purchase iron/folic acid tablets (control, n = 112)
Study: 11411812
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment during the 24-week open-label continuation phase
Study: 9827122
Drug: Local solution
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local solution based on 'pain de singe' (baobab fruit)
Study: 9827122
Drug: WHO standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO standard solution
Study: 8314474
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units (MU) interferon three times weekly for six months
Study: 8314474
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU interferon three times weekly for the first six months, 2 MU for the next three months, and 1 MU for the last three months
Study: 8314474
Drug: Longer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer treatment (12 months)
Study: 8314474
Drug: Shorter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter treatment (6 months)
Study: 3555164
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus 1 ml normal saline (Group I)
Study: 3555164
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus 0.2 mg epinephrine (Group II)
Study: 3555164
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus 0.15 mg clonidine (Group III)
Study: 30007057
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg orally 2 hours before surgery and 150 mg at 12 and 24 hours after surgery
Study: 21562755
Drug: Prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30 mg once daily
Study: 21562755
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg once daily
Study: 22972030
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (plasma insulin 200 pmol/l)
Study: 22972030
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (plasma insulin 600 pmol/l)
Study: 19819661
Drug: Modified smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified smoking cessation treatment for depressive smokers
Study: 19819661
Drug: Modified smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified smoking cessation treatment for higher dependence smokers
Study: 17211088
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg monthly ibandronate
Study: 17211088
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg bi‐monthly ibandronate
Study: 15911865
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m(2) every 3 weeks (CPT)
Study: 15911865
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m(2) day 1 plus topotecan 0.75 mg/m(2) days 1 to 3 every 3 weeks (CT)
Study: 12479047
Drug: Epristeride 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epristeride 5 mg p.o., twice daily for 120 days
Study: 2533526
Drug: Nafarelin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (200 micrograms twice daily intranasally for 3 or 6 months)
Study: 6359
Drug: Cimetidine 25
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 25 mg
Study: 23475016
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training (multimedia-based training + practical training)
Study: 19553301
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g oil-rich fish (salmon) per week (n = 82)
Study: 19553301
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g lean fish (cod) per week (n = 78)
Study: 17548749
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus liothyronine
Study: 9591932
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg imidapril once per day for 7 days
Study: 25594526
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol, programmed to start stimulatory agents on a Friday, with oral 2mg estradiol valerate twice a day from the 2nd day of cycle until the first Friday to follow.
Study: 25594526
Drug: Long luteal
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long luteal GnRH agonist protocol.
Study: 25594526
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol.
Study: 25594526
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist protocol.
Study: 11333992
Drug: Carvedilol (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (6.25 to 50 mg twice daily)
Study: 9284847
Drug: Pindolol with
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol with 1.5 gm ammonium chloride (NH4Cl) four times daily for 3 days
Study: 9284847
Drug: Pindolol with
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol with 200 mg trimethoprim once daily for 3 days
Study: 7904188
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate with aspirin
Study: 3554082
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 25,000 IU of retinol daily for up to 3 months
Study: 3554082
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 50,000 IU of retinol daily for up to 3 months
Study: 3554082
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of retinol supplementation
Study: 15922816
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (BT) nasal spray 1 mg
Study: 15922816
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (BT) nasal spray 2 mg
Study: 7883742
Drug: Electroshock therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroshock therapy
Study: 2568348
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg and 200 mg)
Study: 2568348
Drug: D-amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (10 mg and 20 mg)
Study: 29770722
Drug: Fluocinonide 0.05%
Normalized name: FLUOCINONIDE 0.05% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.05% gel
Study: 29770722
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate 0.1% lotion
Study: 29770722
Drug: Fluocinonide 0.05%
Normalized name: FLUOCINONIDE 0.05% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.05% solution
Study: 31127666
Drug: Reprieve therapy
Normalized name: Bepreve
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reprieve therapy (with normal saline for matched volume replacement)
Study: 31127666
Drug: Standard diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diuretic therapy
Study: 31127666
Drug: Reprieve therapy
Normalized name: Bepreve
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reprieve therapy
Study: 28581401
Drug: Hippocampal-sparing prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippocampal-sparing prophylactic cranial irradiation (PCI) 25 Gy/10 fractions, with a mean hippocampal dose limited to <8 Gy.
Study: 23570586
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) at 200 or 150 mg×m(‐2)d(‐1) for 5 days, repeated every 28 days
Study: 23570586
Drug: Semustine (Me‐CCNU)
Normalized name: Lomustine
DrugBank: Semustine (DB13647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semustine (Me‐CCNU) at 150 mg×m(‐2)×d(‐1) once, repeated every 28 days
Study: 25474278
Drug: Oxaliplatin and
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and fluoropyrimidine-based chemotherapy
Study: 25474278
Drug: 2nd and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd and/or 3rd line chemotherapy with irinotecan and/or cetuximab
Study: 22508711
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (1 mU/min · kg)
Study: 22508711
Drug: Candesartan (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (32 mg) + Insulin infusion
Study: 21547174
Drug: Palonosetron 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 75 μg intravenously as a bolus before induction of anaesthesia
Study: 21547174
Drug: Granisetron 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2.5 mg intravenously as a bolus before induction of anaesthesia
Study: 12810240
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg tid
Study: 1806619
Drug: Clozapine, 150-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine, 150-250 mg p.d.
Study: 1806619
Drug: Haloperidol, 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol, 20-40 mg p.d.
Study: 6412376
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution (group A)
Study: 6412376
Drug: Dextrose‐electrolyte‐calcium solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose‐electrolyte‐calcium solution (group B)
Study: 30866088
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg
Study: 21312292
Drug: Reboxetine 8
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 8 mg/day (twice daily)
Study: 15797959
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg daily), Vitamin D (800 IU daily), and sex steroid replacement therapy (estrogen for females, testosterone for males)
Study: 15797959
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg daily), Vitamin D (800 IU daily), sex steroid replacement therapy (estrogen for females, testosterone for males), and six iv infusions of pamidronate (60 mg each)
Study: 8745456
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (radiotherapy + surgery) in 46 patients
Study: 2565582
Drug: Buspirone (acute:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (acute: 15 mg; subchronic: 5 mg t.i.d.; Day 7: 5 mg)
Study: 2565582
Drug: Bromazepam (acute:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (acute: 6 mg; subchronic: 2 mg t.i.d.; Day 7: 2 mg)
Study: 937075
Drug: Lanoxin tablets
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lanoxin tablets
Study: 937075
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of digoxin
Study: 937075
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (tablets and oral solution)
Study: 20616624
Drug: Brief dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief dynamic therapy (BDT) added to pharmacotherapy (n = 27)
Study: 20616624
Drug: Pharmacotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy alone (n = 30)
Study: 17653509
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without statin
Study: 10530677
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 600 mg, 1200 mg, or 2400 mg daily
Study: 10530677
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 300 mg/day or 3600 mg/day
Study: 10530677
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 300 mg/day, 900 mg/day, or 1800 mg/day
Study: 7502570
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg piroximone
Study: 7502570
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg piroximone
Study: 7502570
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg piroximone
Study: 7502570
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg piroximone
Study: 2274638
Drug: Nadolol, 80
Normalized name: Nadolol, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 80 to 120 mg per day
Study: 28820635
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cell infusion after FOLFOX4 chemotherapy
Study: 28820635
Drug: FOLFOX4 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 chemotherapy